Sign in
Taking people in PolandPhase 3

Sacubitril/valsartan to prevent heart damage during breast cancer treatment

Tests sacubitril/valsartan in adults with breast cancer receiving chemotherapy to protect the heart.

Key facts

Who runs it
Slaskie Centrum Chorob Serca W Zabrzu
Where
Gdansk, Gliwice, Kielce, Opole, and Zabrze, PolandSee the 5 sites
Registry title
Sacubitril/Valsartan in prevention of heart damage during breast cancer treatment
Status
Recruiting
Phase
Phase 3
People taking part
600 people, planned
Started
17 Apr 2024
Expected to end
30 Sept 2027
Type of study
Interventional
Record updated
26 October 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with breast cancer who are going to get anthracyclines and/or anti-HER2 drugs and still have normal heart function. It tests whether sacubitril/valsartan can prevent heart damage from the treatment.

Age
18 years and over
Sex
Women only
Disease stage
Breast cancer confirmed by tissue test, stage IA-IIIC or oligometastatic stage IV, with a plan for radical treatment. General health status ECOG 0-2.
Earlier treatment
A plan to use anthracyclines and/or anti-HER2 drugs. No earlier anthracycline chemotherapy and no earlier left-sided radiotherapy.
Biomarker or test result
Tumor tests done (ER, PR, HER2, Ki67). Heart pumping function (LVEF) of 50% or more on an ultrasound scan. Sinus rhythm.

Main reasons for not taking part

  • Pregnancy
  • Heart failure with symptoms (NYHA II-IV)
  • Heart attack within the last 3 months
  • Kidney function GFR below 30 ml/min/1.73 m2 or potassium above 5.5 mmol/L
  • Expected survival under 12 months

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Written informed consent
  • Sinus rhythm
  • Female gender, aged 18 years and over
  • Patients with histologically confirmed breast cancer and complete assessment of tumor phenotype (ER, PR, HER2, Ki67)
  • Ability to take oral medication and willingness to adhere to the planned regimen
  • Tumor grade IA-IIIC or oligometastatic grade IV
  • Radical treatment plan including surgery or post-radical surgical treatment
  • Plan of use of systemic treatment (preoperative, postoperative or combined) with anthracyclines and/or anti-HER2 drugs
  • ECOG 0-2 general status
  • LVEF ≥ 50% as assessed by echocardiography

Who cannot take part

  • Prior anthracycline-based chemotherapy and/or left-sided radiotherapy (prior to diagnosis of the cancer being the present cause of XML File Identifier: xW+Ea9mm17kcx3fLB1UWMlFS0h4=Page 16/27 therapy)
  • Active untreated liver disease
  • Conditions/circumstances that may lead to non-compliance with medical staff recommendations (e.g. active drug/alcohol dependence, poorly controlled mental illness)
  • Significant valvular disease, symptomatic coronary artery disease (CCS>2), significant AV block, symptomatic sinus node dysfunction
  • GFR<30 ml/min/1.73 m2 (screening visit)
  • Lack of Written informed consent
  • Contraindications to ACE-I/ARB or LCZ696 if not listed among criteria
  • Pregnancy
  • Clinically relevant HF (NYHA II-IV)
  • MI within the last < 3 months
  • Symptomatic hypotension or SBP < 90 mmHg
  • Expected survival <12 months
  • K+>5.5mmol/L (screening visit)

Where in Poland

  • Medical University Of GdanskGdansk, PolandTaking people
  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut BadawczyGliwice, PolandTaking people
  • Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej w KielcachKielce, PolandTaking people
  • Opolskie Centrum Onkologii Im. Prof. Tadeusza Koszarowskiego W Opolu Samodzielny Publiczny Zaklad Opieki ZdrowotnejOpole, PolandTaking people
  • Śląskie Centrum Chorób Serca w ZabrzuZabrze, PolandTaking people

About the trial

What the trial wants to find out

Estimation of whether prophylactic use of sacubitril/valsartan will prevent cardiotoxicity associated with systemic breast cancer treatment, defined as a decrease in left ventricular ejection fraction ≥ 5% in an ultrasound scan during 24 months from randomization.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Sacubitril/Valsartan in PriMAry preventIoN of the cardiotoxicity of systematic breaST canceR trEAtMent. Randomized, multicenter, double-blind, placebo-controlled study.
Plain-language title
Sacubitril/valsartan to prevent heart damage during breast cancer treatmentGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
26 October 2025